This study checks how well a treatment called OTX-TKI (axitinib implant) works and how safe it is for people with a condition called Neovascular Age-Related Macular Degeneration (nAMD). This condition affects the eyes and can cause vision problems as people get older. The treatment is given as an injection into the eye.

To join this study, you must be at least 50 years old and not have had any prior treatment for nAMD in either eye. You should also have good vision, which means a Best Corrected Visual Acuity (BCVA) score that is close to perfect vision. You cannot join if you have only one working eye or other eye issues like scars or damage.

• The study involves multiple visits to check your eye health.
• Participants may receive compensation for their time and travel.
• There might be some risks, such as eye irritation from the injection.